1[1]Thuillez C, Richard C, Loueslati H. The hemodynamic action of perindopril in patient with congestive heart failure. J Cardiovasc Pharmacol, 1990, 15:527
2[2]MacFadyen R J, Lees KR, Reid JL. A placebo controlled trial of ACE inhibitor in refractory chronic congestive heart failure.University of Glasgow. Br Heart, 1991, 66:206
3[3]Iain B. Squire MB. Long-term tolerance and effect of perinodoril to patient with chronic congestive heart failure. Clin Cardiol.1996, 19 (Suppl 1):9-15
4[4]Jones JV. Perindopril. The British Journal of Cardiology,1998, 5(5):268
5[5]Schoenberger JA. Converting enzyme inhibitors in the treatment of hypertension. In: Punzi HA, Flamenbaum W, eds. Hypertension Volume J. New York: Futura Publishing, 1989: 155-166
3Elliott HL,Meredith PA.Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade:further analysis of the‘ACTION'database in patients with angina[J].J Hum Hypertens,2011,25(1):63-70.
4Briguori C,Airoldi F,Morici N,et al.New pharmacological protocols to prevent or reduce contrast media nephropathy[J].Minerva Cardioangiol,2005,53(1):49-58.
8Rihal CS,Textor SC,Grill DE,et al.Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention[J].Circulation,2002,105(19):2259-2264.
9Nikolsky E,Aymong ED,Dangas G,et al.Radiocontrast nephropathy:identifying the high-risk patient and the implications exacerbating renal function[J].Rev Cardiovasc Med,2003,4(Suppl 1):S7-S14.
10Umruddin Z,Moe K,Superdock K.ACE inhibitor or angiotensinⅡreceptor blocker use is a risk factor for contrast-induced nephropathy[J].J Nephrol,2012,25(5):776-781.
